Current and emerging treatment options for central serous chorioretinopathy

References

• Van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003
   PubMed Web of Science ®Google Scholar
• Fine SL, Owens SL. Central serous retinopathy in a 7-year-old girl. Am J Ophthalmol. 1980 Jun;90(6):871–873. doi: 10.1016/S0002-9394(14)75205-5
   PubMed Web of Science ®Google Scholar
• Castro-Correia J, Coutinho MF, Rosas V, et al. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992;81(4):379–386. doi: 10.1007/BF00169099
   PubMed Web of Science ®Google Scholar
• Breukink MB, Dingemans AJM, Den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2017 Jan;11:39–46. doi: 10.2147/OPTH.S115685
   PubMed Web of Science ®Google Scholar
• Von Graefe A. Nachträgliche Bemerkungen über die modificirte Linearextraction. Graefes Arch Clin Exp Ophthalmol. 1866;12(1):211–215. doi: 10.1007/BF02720786
   Google Scholar
• Kitahara S. Ueber klinische beobachtungen bei der in Japan häufig vorkommenden chorioretinitis centralis serosa. Klin Monatsbl Augenheilkd. 1936;97:345–362.
   Google Scholar
• Horniker EK. Monatsblätter Augenheilkd. 1937;98:487.
   Google Scholar
• Duke-Elder S. Text-book of ophthalmology. 1940;3:2592.
   Google Scholar
• Bennett G. Central serous retinopathy. Br J Ophthalmol. 1955 Oct;39(10):605–618. doi: 10.1136/bjo.39.10.605
   PubMedGoogle Scholar
• Maumenee AE. Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol. 1965 Jul;69:605–613.
   PubMedGoogle Scholar
• Gass JD, Gass M. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967 Mar;63(3):1–139. doi: 10.1016/0002-9394(67)90026-8
   Google Scholar
• Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41. doi: 10.1007/BF00225936
   PubMed Web of Science ®Google Scholar
• Negi A, Marmor MF. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol. 1984 Mar;102(3):445–449. doi: 10.1001/archopht.1984.01040030359038
   PubMedGoogle Scholar
• Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–213. doi: 10.1097/00006982-199616030-00004
   PubMed Web of Science ®Google Scholar
• Mohabati D, van Rijssen TJ, van Dijk EHC, et al. Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol. 2018 Jun;12:1061–1070. doi: 10.2147/OPTH.S160956
   PubMed Web of Science ®Google Scholar
• Agrawal R, Chhablani J, Tan K-A, et al. Choroidal vascularity index in central serous chorioretinopathy. Retina. 2016 Aug 23;36(9):1646–1651. doi: 10.1097/IAE.0000000000001040
   PubMed Web of Science ®Google Scholar
• Gal-Or O, Dansingani KK, Sebrow D, et al. Inner choroidal flow signal attenuation in pachychoroid disease: optical coherence tomography angiography. Retina. 2018 Oct;38(10):1984–1992.
   PubMed Web of Science ®Google Scholar
• Teussink MM, Breukink MB, Van Grinsven MJ, et al. Oct angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2015 Sep;56(9):5229–5237.
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye. 2019 Jan;33(1):14–33.
   PubMed Web of Science ®Google Scholar
• Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015 Jan;35(1):1–9. doi: 10.1097/IAE.0000000000000331
   PubMed Web of Science ®Google Scholar
• Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009 May;147(5):811–815. doi: 10.1016/j.ajo.2008.12.008
   PubMed Web of Science ®Google Scholar
• Carnevali A, Capuano V, Sacconi R, et al. OCT angiography of treatment-naïve quiescent choroidal neovascularization in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci. 2017 Jun 1;1(4):328–332. doi: 10.1016/j.oret.2017.01.003
   Google Scholar
• Fung A, Yannuzzi L, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Clin Exp Ophthalmol. 2012 Dec;32(Suppl. 9):1829–1837. doi: 10.1097/IAE.0b013e3182680a66
   Google Scholar
• Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2022 Jan;86:100973. doi: 10.1016/j.preteyeres.2021.100973
   PubMed Web of Science ®Google Scholar
• Giovansili I, Belange G, Affortit A. Cushing disease revealed by bilateral atypical central serous chorioretinopathy: case report. Endocr Pract. 2013 Sep;19(5):e129–33. doi: 10.4158/EP12389.CR
   PubMed Web of Science ®Google Scholar
• Behar-Cohen F, Zhao M. Mineralocorticoid pathway in retinal health and diseases. Br J Pharmacol. 2022 Jul 1;179(13):3190–3204. doi: 10.1111/bph.15770
   PubMed Web of Science ®Google Scholar
• Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmol. 2004 Feb;111(2):244–249.
   PubMed Web of Science ®Google Scholar
• Genovese G, Meduri A, Muscatello MRA, et al. Central serous chorioretinopathy and personality characteristics: a systematic review of scientific evidence over the last 10 years (2010 to 2020). Medicina (Kaunas). 2021 Jun 16;57(6):628. doi: 10.3390/medicina57060628
   PubMed Web of Science ®Google Scholar
• Chhablani J, Cohen FB, Central Serous Chorioretinopathy International Group; Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retina. 2020 Nov;4(11):1043–1046. doi: 10.1016/j.oret.2020.07.026
   PubMedGoogle Scholar
• Bressler S, Susan B, Almukhtar, et al. Green or yellow laser treatment for diabetic macular edema. Retina. 2013;33(10):2080–2088. doi: 10.1097/IAE.0b013e318295f744
   PubMed Web of Science ®Google Scholar
• Verma L, Sinha R, Venkatesh P, et al. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol. 2004 Oct 29;4(1):15. doi: 10.1186/1471-2415-4-15
   PubMedGoogle Scholar
• Gupta A, Tripathy K. Central serous chorioretinopathy. Treasure Island (FL): StatPearls Publishing;2023 Dec 11.
   Google Scholar
• Daruich A, Matet A, Dirani A. Central serous chorioretinopathy: recent findings and new physio- pathology hypothesis. Prog Retin Eye Res. 2015;48:82–118. doi: 10.1016/j.preteyeres.2015.05.003
   PubMed Web of Science ®Google Scholar
• Ficker L, Vafidis G, While A, et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988 Nov;72(11):829–834.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yao J, Jiang Q, et al. Efficacy of navigated laser photocoagulation for chronic central serous chorioretinopathy: a retrospective observational study. Dis Markers. 2022;2022:1–8. doi: 10.1155/2022/7792291
   Web of Science ®Google Scholar
• Sun Z, Huang Y, Nie C, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond). 2020 Sep;34(9):1592–1599.
   PubMed Web of Science ®Google Scholar
• Amoroso F, Pedinielli A, Cohen SY, et al. Navigated micropulse laser for central serous chorioretinopathy: efficacy, safety, and predictive factors of treatment response. Eur J Ophthalmol. 2022 Sep;32(5):2810–2818.
   PubMed Web of Science ®Google Scholar
• Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmol. 1997;104(12):2030–2038. doi: 10.1016/S0161-6420(97)30061-X
   PubMed Web of Science ®Google Scholar
• Van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmol. 2018 Oct;125(10):1547–1555. doi: 10.1016/j.ophtha.2018.04.021
   PubMed Web of Science ®Google Scholar
• Chen S-N, Hwang J-F, Tseng L-F, et al. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmol. 2008 Dec;115(12):2229–2234.
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Furlan F, Morgante L, et al. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–940. doi: 10.1177/112067210801800613
   PubMed Web of Science ®Google Scholar
• Luttrull JK. Comment on: focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report No. 3. Am J Ophthalmol. 2020 Apr 1;212:186–187. doi: 10.1016/j.ajo.2019.10.037
   PubMed Web of Science ®Google Scholar
• van Dijk EH, Fauser S, Breukink MB. et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmol. 2019 Apr 1;126(4):e29–e30. doi: 10.1016/j.ophtha.2018.11.004
   PubMed Web of Science ®Google Scholar
• Iacono P, Da Pozzo S, Varano M, et al. Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: a review of data and efficacy. Pharmaceuticals. 2020;13(11):349. doi: 10.3390/ph13110349
   Web of Science ®Google Scholar
• Battaglia Parodi M, Arrigo A, Iacono P, et al. Central serous chorioretinopathy: treatment with laser. Pharmaceuticals. 2020;13(11):359. doi: 10.3390/ph13110359
   Web of Science ®Google Scholar
• Roca JA, Wu L, Fromow-Guerra J, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the pan-american collaborative retina study (PACORES) group. Br J Ophthalmol. 2018 Dec;102(12):1696–1700.
   PubMed Web of Science ®Google Scholar
• Park YG, Kang S, Kim M, et al. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients. Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1375–1383.
   PubMed Web of Science ®Google Scholar
• Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (Lond). 2018 Apr;32(4):726–733. doi: 10.1038/eye.2017.293
   PubMed Web of Science ®Google Scholar
• Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye. 2016;30(10):1371–1377. doi: 10.1038/eye.2016.142
   PubMed Web of Science ®Google Scholar
• Scholz P, Ersoy L, Boon CJF, et al. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica. 1 Oct 2015;234(4):189–194. doi: 10.1159/000439600
   PubMed Web of Science ®Google Scholar
• Altınel MG, Acikalin B, Gunes H, et al. Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36(7):1505–1514. doi: 10.1007/s10103-020-03225-6
   PubMed Web of Science ®Google Scholar
• Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Graefes Arch Clin Exp Ophthalmol. 2017;255(12):255, 2299–2306. doi: 10.1007/s00417-017-3783-x
   PubMed Web of Science ®Google Scholar
• Van Rijssen TJ, van Dijk EHC, Scholz P, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report No. 3. Am J Ophthalmol. 2019 Sep;205:1–10. doi: 10.1016/j.ajo.2019.03.025
   PubMed Web of Science ®Google Scholar
• Schworm B, Siedlecki J, Keidel LF, et al. Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2021 Nov;259(11):3271–3281.
   PubMed Web of Science ®Google Scholar
• Feenstra HMA, Hahn LC, van Rijssen TJ, et al. Efficacy of half-dose photodynamic therapy versus high-density subthreshold micropulse laser for treating pigment epithelial detachments in chronic central serous chorioretinopathy. Retina.2022 Apr;42(4):721–729.
   PubMed Web of Science ®Google Scholar
• Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmol. 1996;103(3):427–438. doi: 10.1016/S0161-6420(96)30675-1
   PubMed Web of Science ®Google Scholar
• Kessel D. Porphyrin-lipoprotein association as a factor in porphyrin localization. Cancer Lett. 1986;33(2):183–188. doi: 10.1016/0304-3835(86)90023-6
   PubMed Web of Science ®Google Scholar
• Roberts WG, Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res. 1992;52(4):924–930.
   PubMed Web of Science ®Google Scholar
• Chan W-M, Lam DSC, Lai TYY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003 Dec;87(12):1453–1458.
   PubMed Web of Science ®Google Scholar
• Alkin Z, Perente I, Ozkaya A, et al. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Clin Ophthalmol. 2014 Apr 5;8:685–690. doi: 10.2147/OPTH.S58617
   PubMedGoogle Scholar
• Stewart JM. Half dose verteporfin PDT for central serous chorioretinopathy. Br J Ophthalmol. 2006 Jul;90(7):805–806. doi: 10.1136/bjo.2006.093328
   PubMed Web of Science ®Google Scholar
• Kumashiro S, Takagi S, Itokawa T, et al. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. BMC Ophthalmol. 2021 May 31;21(1):241. doi: 10.1186/s12886-021-01980-w
   PubMed Web of Science ®Google Scholar
• Nicoló M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014 May;157(5):1033–1037.e2.
   PubMed Web of Science ®Google Scholar
• Dang Y, Sun X, Xu Y, et al. Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy. Ther Clin Risk Manag. 2014;10:37–43. doi: 10.2147/TCRM.S54213
   PubMed Web of Science ®Google Scholar
• Honda S, Kohno T, Yamamoto M, et al. Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases. 2022. Sci Rep. 2022;12(1):9105. doi: 10.1038/s41598-022-13208-y
   PubMed Web of Science ®Google Scholar
• Van Dijk EHC, Dijkman G, Theelen T, et al. Short-term findings on optical coherence tomography and microperimetry in chronic central serous chorioretinopathy patients treated with half-dose photodynamic therapy. Retin Cases Brief Rep. 2018 Sep;12(4):S266–S271.
   PubMedGoogle Scholar
• Hu J, Qu J, Li M, et al. Optical coherence tomography angiography-guided photodynamic therapy for acute central serous chorioretinopathy. Retina. 2021 Jan;41(1):189–198.
   PubMed Web of Science ®Google Scholar
• Van Rijssen TJ, Singh SR, van Dijk EHC, et al. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1191–1197.
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Scholz P, et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial. Am J Ophthalmol. 2020 Aug;216:80–89. doi: 10.1016/j.ajo.2020.04.007
   PubMed Web of Science ®Google Scholar
• Van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022 Jan;233:101–110. doi: 10.1016/j.ajo.2021.06.020
   PubMed Web of Science ®Google Scholar
• Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmol.2014 Feb;121(2):558–565.
   PubMed Web of Science ®Google Scholar
• Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014 Feb;157(2):366–373.e1. doi: 10.1016/j.ajo.2013.10.013
   PubMed Web of Science ®Google Scholar
• Chan W-M, Lai TYY, Lai RYK, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy. One-year results of a randomized controlled trial. Ophthalmol. 2008 Oct;115(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Alkin Z, Ozveren M, et al. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study. Eye (Lond). 2016 Jul 1;30(7):1005–1010. doi: 10.1038/eye.2016.79
   PubMed Web of Science ®Google Scholar
• Arif F, Pryds A, Larsen M, et al. Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy. Acta Ophthalmol. 2018 Dec 1;96(8):821–827. doi: 10.1111/aos.13838
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol. 2007;91(6):827–831.
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration twelve-month results. Ophthalmol. 2016 Mar 1;123(3):617–624. doi: 10.1016/j.ophtha.2015.10.039
   PubMed Web of Science ®Google Scholar
• Nourinia R, Ahmadieh H, Nekoei E, et al. Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity. Retina. 2018 May 1;38(5):970–975. doi: 10.1097/IAE.0000000000001645
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmol. 2018 May 1;125(5):708–724. doi: 10.1016/j.ophtha.2017.11.019
   PubMed Web of Science ®Google Scholar
• Gabriel C, Lupidi M, Coscas F, et al. Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Invest Ophthalmol Visual Sci. 2015;56(5):3187–3195.
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye (Lond). 2019 Jan 1;33(1):14–33. doi: 10.1038/s41433-018-0158-4
   PubMed Web of Science ®Google Scholar
• Torres-Soriano ME, García-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2008;246(9):1235–1239.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee S-C, Lee S-J. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152–157. doi: 10.1159/000345495
   PubMed Web of Science ®Google Scholar
• Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015 Jun 12;29(6):732–741. doi: 10.1038/eye.2015.58
   PubMed Web of Science ®Google Scholar
• Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010;35(2):91–98.
   PubMed Web of Science ®Google Scholar
• Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Nov;152(5):784–792.e2.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Romano MR, Danzi P, et al. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012 Nov;56(6):608–612.
   PubMed Web of Science ®Google Scholar
• Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018 Jan 1;38(8):1464–1477. doi: 10.1097/IAE.0000000000001744
   PubMed Web of Science ®Google Scholar
• Peiretti E, Caminiti G, Serra R, et al. Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina. 2018 Aug 1;38(8):1526–1532. doi: 10.1097/IAE.0000000000001750
   PubMed Web of Science ®Google Scholar
• Chhablani J, Kozak I, Pichi F, et al. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina. 2015;35(12):2489–2497. doi: 10.1097/IAE.0000000000000655
   PubMed Web of Science ®Google Scholar
• Sonoda N, Araki T, Komuku Y, et al. Photodynamic therapy for central serous chorioretinopathy with choroidal neovascularization on optical coherence tomography angiography combined with intravitreal anti-vascular endothelial growth factor therapy or alone. Invest Ophthalmol Vis Sci. 2019 Jul 1;60:(9).
   Web of Science ®Google Scholar
• Smretschnig E, Hagen S, Glittenberg C, et al. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye (Lond). 2016 Jun 1;30(6):805–811. doi: 10.1038/eye.2016.41
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151. doi: 10.1210/er.2010-0013
   PubMed Web of Science ®Google Scholar
• Tsai D-C, Chen S-J, Huang C-C, et al. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina. 2014 Sep;34(9):1867–1874.
   PubMed Web of Science ®Google Scholar
• Imasawa M, Ohshiro T, Gotoh T, et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand. 2005;83(1):132–133. doi: 10.1111/j.1600-0420.2005.00379.x
   PubMedGoogle Scholar
• Zhao M, Valamanesh FC, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 2010;24(9):3405–3415. doi: 10.1096/fj.09-154344
   PubMed Web of Science ®Google Scholar
• Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33(10):10 (2096–2102). doi: 10.1097/IAE.0b013e318297a07a
   Web of Science ®Google Scholar
• Carone L, Oxberry SG, Twycross R, et al. Spironolactone. J Pain Symptom Manage. 2017 Feb 1;53(2):288–292. doi: 10.1016/j.jpainsymman.2016.12.320
   PubMedGoogle Scholar
• Yavuz S, Balsak S, Karahan M, et al. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. J Fr Ophtalmol. 2021 Jan;44(1):13–23.
   PubMed Web of Science ®Google Scholar
• Sun X, Shuai Y, Fang W, et al. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. 2018 Aug 1;102(8):1060–1065. doi: 10.1136/bjophthalmol-2017-311096
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Amirsardari A, Habibi A. Visual and anatomical outcomes of spironolactone therapy in patients with chronic central serous chorioretinopathy. J Ophthalmic Vis Res. 2017 Jul;12(3):281–289. doi: 10.4103/jovr.jovr_139_16
   PubMedGoogle Scholar
• Han JY, Kim YJ, Choi EY, et al. Therapeutic efficacy of spironolactone for central serous chorioretinopathy. Yonsei Med J. 2022 Apr 1;63(4):365–371. doi: 10.3349/ymj.2022.63.4.365
   PubMed Web of Science ®Google Scholar
• Felipe CQ, Biancardi AL, Civile VT, et al. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retina Vitreous. 2022 Jun 7;8(1):34. doi: 10.1186/s40942-022-00385-1
   PubMedGoogle Scholar
• Venkatesh R, Prabhu V, Joshi A, et al. Real-world practice patterns of eplerenone use for central serous chorioretinopathy. Int J Retina Vitreous. 2023 Oct 2;9(1):61. doi: 10.1186/s40942-023-00500-w
   PubMedGoogle Scholar
• Sinawat S, Thongmee W, Sanguansak T, et al. Oral spironolactone versus conservative treatment for non-resolving central serous chorioretinopathy in real-life practice. Clin Ophthalmol. 2020;14:1725–1734. doi: 10.2147/OPTH.S260998
   PubMed Web of Science ®Google Scholar
• Tam TS, Wu MH, Masson SC, et al. Eplerenone for hypertension. Cochrane Database Syst Rev. 2017 Feb 28;2017(2): CD008996. doi: 10.1002/14651858.CD008996.pub2
   Google Scholar
• Sacconi R, Borrelli E, Querques G, et al. Eplerenone for chronic central serous chorioretinopathy. Lancet. 2020 Nov 14;396(10262):1556. doi: 10.1016/S0140-6736(20)31610-X
   PubMedGoogle Scholar
• Iqbal F, Iqbal K, Inayat B. Eplerenone treatment in chronic central serous chorioretinopathy. Cureus. 2021 Oct 1;13(10):e18415. doi: 10.7759/cureus.18415
   PubMed Web of Science ®Google Scholar
• Fraenkel D, Suffo S, Langenbucher A. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2021 Jul;31(4):1885–1891. doi: 10.1177/1120672120952648
   PubMed Web of Science ®Google Scholar
• Lotery A, Sivaprasad S, O’Connell A, et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. Efficacy And Mech Eval. 2021 Jan;8(2):1–82. Southampton (UK): NIHR Journals Library. doi: 10.3310/eme08020
   Google Scholar
• Petkovsek DS, Cherfan DG, Conti FF, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020 Feb;104(2):182–187.
   PubMed Web of Science ®Google Scholar
• Clemente L, Cennamo G, Montorio D, et al. OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: a comparative study. Eur J Ophthalmol. 2023 Mar;33(2):1090–1096.
   Web of Science ®Google Scholar
• Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011 Oct;31(9):1928–1936. doi: 10.1097/IAE.0b013e31821c3ef6
   PubMed Web of Science ®Google Scholar
• Fusi-Rubiano W, Saedon H, Patel V, et al. Oral medications for central serous chorioretinopathy: a literature review. Eye (Lond). 2020 May;34(5):809–824.
   PubMed Web of Science ®Google Scholar
• Ogrodowczyk M, Dettlaff K, Jelinska A. Beta-blockers: Current state of knowledge and perspectives. Mini Rev Med Chem. 2016;16(1):40–54. doi: 10.2174/1389557515666151016125948
   PubMed Web of Science ®Google Scholar
• Browning DJ. Nadolol in the treatment of central serous retinopathy. Am J Ophthalmol. 1993 Dec 15;116(6):770–771. doi: 10.1016/S0002-9394(14)73483-X
   PubMed Web of Science ®Google Scholar
• Fabianová J, Porubská M, Cepilová Z. Central serous chorioretinopathy–treatment with beta blockers. Cesk Slov Oftalmol. 1998 Nov;54(6):401–404.
   PubMedGoogle Scholar
• Kianersi F, Fesharaki F. Effects of propranolol in patients with central serous chorioretinopathy. J Res Med Sci. 2008 May;13(3):103–107.
   Web of Science ®Google Scholar
• Chrapek O, Jirkova B, Kandrnal V, et al. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):120–123.
   PubMed Web of Science ®Google Scholar
• Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988 Sep;106(9):1190–1195. doi: 10.1001/archopht.1988.01060140350030
   PubMedGoogle Scholar
• Tripathi RC, Fekrat S, Tripathi BJ, et al. A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy. Ann Ophthalmol. 1991 Apr;23(4):127–129.
   PubMedGoogle Scholar
• Pikkel J, Beiran I, Ophir A, et al. Acetazolamide for central serous retinopathy. Ophthalmol. 2002 Sep;109(9):1723–1725. doi: 10.1016/S0161-6420(02)01157-0
   PubMed Web of Science ®Google Scholar
• Kwak JH, Hong SW, Ra H, et al. Effect of Acetazolamide on choroidal morphology in central serous chorioretinopathy. Korean J Ophthalmol. 2019;33(6):493. doi: 10.3341/kjo.2019.0063
   PubMedGoogle Scholar
• Yamada R, Yamada S, Ishii A, et al. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1993 Aug;97(8):955–960.
   PubMedGoogle Scholar
• Iijima H, Iida T, Murayama K, et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. 1999 Apr;127(4):477–478.
   PubMed Web of Science ®Google Scholar
• Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903. doi: 10.2147/OPTH.S12583
   PubMedGoogle Scholar
• Chou SC, Lin JD. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing’s disease. Endocr J. 2000;47(4):401–406. doi: 10.1507/endocrj.47.401
   PubMed Web of Science ®Google Scholar
• Meyerle CB, Freund KB, Bhatnagar P, et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007 Sep;27(7):943–946.
   PubMed Web of Science ®Google Scholar
• Golshahi A, Klingmüller D, Holz FG, et al. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010 Aug;88(5):576–581. doi: 10.1111/j.1755-3768.2008.01467.x. Epub 2009 May 12. PMID: 19456313.
   PubMed Web of Science ®Google Scholar
• Chantarasorn Y, Rasmidatta K, Pokawattana I, et al. Effects of ketoconazole on the clinical recovery in central serous chorioretinopathy. Clin Ophthalmol. 2022;16:1871–1882. doi: 10.2147/OPTH.S368427
   PubMed Web of Science ®Google Scholar
• Chaudhary UB, Turner JSF. Finasteride. Expert Opin Drug Metab Toxicol. 2010 Jul;6(7):873–881. doi: 10.1517/17425255.2010.495944
   PubMed Web of Science ®Google Scholar
• Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011 Apr;31(4):766–771.
   PubMed Web of Science ®Google Scholar
• Moisseiev E, Holmes AJ, Moshiri A, et al. Finasteride is effective for the treatment of central serous chorioretinopathy. Eye (Lond).2016 Jun;30(6):850–856.
   PubMed Web of Science ®Google Scholar
• Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol. 2012;12(1):20. doi: 10.1186/1471-2415-12-20
   PubMedGoogle Scholar
• Mazzolani F. Pilot study of oral administration of a curcumin-phospholipid for- mulation for treatment of central serous chorioretinopathy. Clin Ophthalmol. 2012;6:801–806. doi: 10.2147/OPTH.S31859
   PubMedGoogle Scholar
• Shinojima A, Sawa M, Sekiryu T, et al. A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica. 2017;237(3):159–166. doi: 10.1159/000455807
   PubMed Web of Science ®Google Scholar
• Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset. J Clin Med. 2019 Sep 1;8(9):1398. doi: 10.3390/jcm8091398
   PubMed Web of Science ®Google Scholar
• Luttrull D. Low-intensity/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina. 2016 Aug 23;36(9):1658–1663. doi: 10.1097/IAE.0000000000001005
   PubMed Web of Science ®Google Scholar